Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
| Autor: | Meha Sharma, Anshita Agarwal, Deepak Khandelwal, Indira Maisnam, Deep Dutta, Rajiv Singla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
safety
medicine.medical_specialty Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Dipeptidyl peptidase-4 inhibitor Type 2 diabetes Placebo Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Internal medicine medicine Dapagliflozin Dipeptidyl-Peptidases and Tripeptidyl-Peptidases humans Piperidones Randomized Controlled Trials as Topic Dipeptidyl-Peptidase IV Inhibitors business.industry medicine.disease RC648-665 Gemigliptin meta-analysis Glimepiride Pyrimidines Diabetes Mellitus Type 2 chemistry type 2 030220 oncology & carcinogenesis Sitagliptin diabetes mellitus Clinical Study Original Article Glycated hemoglobin business medicine.drug glycated hemoglobin |
| Zdroj: | Endocrinology and Metabolism, Vol 36, Iss 2, Pp 374-387 (2021) Endocrinology and Metabolism |
| ISSN: | 2093-5978 |
| Popis: | Background: No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.Results: Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I2=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); PI2=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c P=0.02; I2=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; PI2=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c P=0.77; I2=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I2=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I2=19%; HCE).Conclusion: Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|